Co-Diagnostics (NASDAQ: CODX) cleared to resume trading on Nasdaq

Rhea-AI Filing Summary

Co-Diagnostics, Inc. reports that Nasdaq has confirmed the company is back in compliance with the $1.00 minimum bid price and other requirements for continued listing on The Nasdaq Capital Market. Trading in its securities is scheduled to resume on Nasdaq with the market open on March 11, 2026.

Nasdaq’s Hearing Panel will monitor the company for one year, through March 9, 2027; if the closing bid price stays below $1.00 for 30 consecutive business days, a delisting determination would be issued, subject to appeal. The company also preliminarily estimates cash and cash equivalents of about $11.9 million as of December 31, 2025, an unaudited figure that may change after year-end closing procedures.

Positive

• Restored Nasdaq compliance and trading: The company has regained compliance with Nasdaq’s $1.00 minimum bid requirement, and its securities are scheduled to resume trading on The Nasdaq Capital Market on March 11, 2026.

Negative

• One-year Nasdaq monitoring and delisting trigger: A Discretionary Panel Monitor runs through March 9, 2027; if the closing bid price stays below $1.00 for 30 consecutive business days, Nasdaq would issue a delisting determination, creating ongoing listing-risk pressure.

Insights

Equity & Listing Standards Analyst

Co-Diagnostics regains Nasdaq compliance but faces a one-year monitoring period.

Co-Diagnostics has restored compliance with Nasdaq’s $1.00 minimum bid requirement, allowing its shares to resume trading on The Nasdaq Capital Market starting March 11, 2026. This removes the immediate overhang of a potential delisting and maintains access to a major trading venue.

The Nasdaq Hearing Panel imposed a Discretionary Panel Monitor through March 9, 2027. If the closing bid stays below $1.00 for 30 straight business days during this period, Nasdaq would issue a delist determination, though the company could appeal and obtain a stay while that process concludes.

The company also disclosed a preliminary, unaudited cash and cash equivalents balance of about $11.9 million as of December 31, 2025, subject to final year-end closing. This snapshot gives a rough indication of available liquidity, but the ultimate picture will depend on the completed audited financial statements.

8-K Event Classification

2 items: 2.02, 8.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001692415 0001692415 2026-03-09 2026-03-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 9, 2026

CO-DIAGNOSTICS, INC.

(Exact name of small business issuer as specified in its charter)

Utah		1-38148		46-2609363
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation or organization)		File Number)		Identification Number)

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices)

(801) 438-1036

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CODX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

The information contained in Item 8.01 of this Current Report on Form 8-K (this “Current Report”), to the extent required, is incorporated into this Item 2.02 by reference.

Item 8.01. Other Events.

Nasdaq Matters

On March 9, 2026, Co-Diagnostics, Inc. (the “Company”) was formally notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has demonstrated compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the Company’s securities will resume trading on Nasdaq effective with the open of the market on March 11, 2026, and the previously disclosed listing matter before the Nasdaq Hearing Panel (the “Panel”) has been closed.

The Panel has imposed a Discretionary Panel Monitor for a period of one year, through March 9, 2027. If during the monitoring period, the Company’s closing bid price falls below $1.00 per share for 30 consecutive business days, the Company will not be eligible for a 180-day compliance period otherwise available under the Nasdaq Listing Rules. Rather, Nasdaq would issue a delist determination, which the Company could then appeal by requesting a hearing before the Panel. Such request would stay any further action by Nasdaq pending the conclusion of the hearing process.

December 31, 2025 Cash and Cash Equivalents

The Company is providing the following information about its preliminary cash and cash equivalents as of December 31, 2025. Based upon preliminary estimates and currently available information, the Company estimates that its cash and cash equivalents were approximately $11.9 million as of December 31, 2025. This amount is unaudited and preliminary and is subject to completion of the Company’s financial closing procedures. As a result, this amount may differ from the amount that will be reflected in the Company’s consolidated financial statements as of and for the year ended December 31, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	CO-DIAGNOSTICS, INC.
Date: March 10, 2026	By:	/s/ Brian Brown
	Name:	Brian Brown
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

FAQ

What Nasdaq decision did Co-Diagnostics (CODX) announce in this 8-K?

Nasdaq notified Co-Diagnostics that it has regained compliance with the $1.00 minimum bid price and all other listing criteria. As a result, the company’s securities will resume trading on The Nasdaq Capital Market beginning March 11, 2026, ending the prior listing matter.

When will Co-Diagnostics stock resume trading on Nasdaq?

Co-Diagnostics states its securities will resume trading on The Nasdaq Capital Market with the market open on March 11, 2026. This follows Nasdaq’s confirmation that the company now complies with the $1.00 bid price requirement and other continued listing standards.

What monitoring conditions did Nasdaq place on Co-Diagnostics (CODX)?

Nasdaq’s Hearing Panel imposed a Discretionary Panel Monitor for one year through March 9, 2027. If the closing bid price stays below $1.00 for 30 consecutive business days during this period, Nasdaq would issue a delisting determination, which the company could appeal.

What happens if Co-Diagnostics’ share price falls below $1.00 again?

If Co-Diagnostics’ closing bid price remains below $1.00 for 30 consecutive business days during the monitoring period, Nasdaq would issue a delist determination. The company could then request a hearing before the Panel, which would stay further action during the hearing process.

How much cash does Co-Diagnostics estimate having at December 31, 2025?

Co-Diagnostics preliminarily estimates cash and cash equivalents of about $11.9 million as of December 31, 2025. This figure is unaudited and subject to change when the company completes its financial closing procedures and issues its consolidated financial statements.

Is Co-Diagnostics’ $11.9 million cash balance final and audited?

No. The approximately $11.9 million in cash and cash equivalents cited for December 31, 2025 is described as preliminary and unaudited. Co-Diagnostics notes it is subject to completion of year-end financial closing and may differ from the final audited financial statements.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB